Results 291 to 300 of about 122,145 (339)
Some of the next articles are maybe not open access.
Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Advances in Chronic Kidney Disease, 2021In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at fasting and in the postprandial phase without an increased ...
Tricò, Domenico, Solini, Anna
openaire +3 more sources
Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Kardiologiia, 2014In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov +2 more
openaire +2 more sources
British Journal of Anaesthesia
The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate. While several multisociety statements have been published recently, the recommendations vary significantly in terms of medication ...
A. Oprea +14 more
semanticscholar +1 more source
The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate. While several multisociety statements have been published recently, the recommendations vary significantly in terms of medication ...
A. Oprea +14 more
semanticscholar +1 more source
Obesity, 2022
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists recently demonstrated 15% to 20% weight loss in adults with obesity, a range which has previously been achieved only with bariatric surgery.
Shohinee Sarma, Patricia Palcu
semanticscholar +1 more source
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists recently demonstrated 15% to 20% weight loss in adults with obesity, a range which has previously been achieved only with bariatric surgery.
Shohinee Sarma, Patricia Palcu
semanticscholar +1 more source
Metabolism: Clinical and Experimental
BACKGROUND AND AIMS While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain.
P. Karakasis +3 more
semanticscholar +1 more source
BACKGROUND AND AIMS While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain.
P. Karakasis +3 more
semanticscholar +1 more source
Spending on Glucagon-Like Peptide-1 Receptor Agonists Among US Adults
JAMA Network OpenThis economic evaluation estimates annual total US spending on glucagon-like peptide-1 receptor agonists from 2018 to 2023.
Stavros Tsipas +4 more
semanticscholar +1 more source
Obesity and Glucagon-Like Peptide-1 Receptor Agonists
JAMAThis Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti +2 more
openaire +2 more sources
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
Trends in Endocrinology & Metabolism, 2016Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on ...
van Raalte, Daniël H, Verchere, C Bruce
openaire +4 more sources
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Clinical Gastroenterology and Hepatology
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Layla A. Abushamat +4 more
semanticscholar +1 more source
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Layla A. Abushamat +4 more
semanticscholar +1 more source